Association Between Systemic Inflammation and Lipid Metabolism in the Development of Preeclampsia

Tamara Gojković; Daniela Ardalić; Gorica Banjac; Jelena Vekić; Aleksandra Zeljković; Jelena Munjas; Milica Miljković-Trailović; Snežana Jovičić; Marija Sarić Matutinović; Vesna Spasojević-Kalimanovska; Željko Miković; Aleksandra Stefanović

doi:10.5937/arhfarm75-55585

Tamara Gojković University of Belgrade - Faculty of Pharmacy, Department of Medical Biochemistry, Belgrade, Serbia
Daniela Ardalić Gynecology and Obstetrics Clinic Narodni Front, Belgrade, Serbia,
Gorica Banjac Gynecology and Obstetrics Clinic Narodni Front, Belgrade, Serbia,
Jelena Vekić University of Belgrade - Faculty of Pharmacy, Department of Medical Biochemistry, Belgrade, Serbia
Aleksandra Zeljković University of Belgrade - Faculty of Pharmacy, Department of Medical Biochemistry, Belgrade, Serbia
Jelena Munjas University of Belgrade - Faculty of Pharmacy, Department of Medical Biochemistry, Belgrade, Serbia
Milica Miljković-Trailović University of Belgrade - Faculty of Pharmacy, Department of Medical Biochemistry, Belgrade, Serbia
Snežana Jovičić University of Belgrade - Faculty of Pharmacy, Department of Medical Biochemistry, Belgrade, Serbia
Marija Sarić Matutinović University of Belgrade - Faculty of Pharmacy, Department of Medical Biochemistry, Belgrade, Serbia
Vesna Spasojević-Kalimanovska University of Belgrade - Faculty of Pharmacy, Department of Medical Biochemistry, Belgrade, Serbia
Željko Miković Clinic for Gynecology and Obstetrics Narodni Front, Belgrade, Serbia; University of Belgrade - Faculty of Medicine, Belgrade, Serbia
Aleksandra Stefanović University of Belgrade - Faculty of Pharmacy, Department of Medical Biochemistry, Belgrade, Serbia

DOI: https://doi.org/10.5937/arhfarm75-55585

Keywords: preeclampsia, high-risk pregnancy, lipid profile, inflamation

Abstract

Preeclampsia (PE) is a pregnancy complication marked by hypertension (≥ 140/90 mmHg) and proteinuria (≥ 300 mg/24 h), with an unclear pathogenesis involving inflammation and dyslipidemia. This study aimed to longitudinally examine changes in lipid status parameters and inflammatory markers in pregnant women at high risk for PE and those who developed PE. Among 91 women, 20 developed PE (PE group), and 71 were high-risk (HR group). Both groups were monitored at four points: T1-first, T2-, T3-third trimester, and T4-pre-delivery. Lipid markers (triglycerides (TG), total cholesterol (TC), HDL-C, LDL-C, apolipoproteins A-I and B-100) and inflammatory markers (high-sensitivity C-reactive protein (hsCRP), resistin, serum amyloid A (SAA), and macrophage chemotactic protein-1 (MCP-1)) were assessed. Results showed significantly higher TG, resistin, and MCP-1 concentrations in the PE group compared to the HR group at T1 (p < 0.05, p < 0.01, p < 0.01, respectively). During pregnancy, both groups exhibited increases in TG, TC, LDL-C, SAA, and MCP-1 (p < 0.001), while HDL-C and resistin increased only in the HR group (p < 0.001). PE development is associated with atherogenic lipid changes, characterized by hypertriglyceridemia and no increase in HDL-C, with elevated SAA potentially diminishing HDL’s protective role.

References

Soma-Pillay P, Nelson-Piercy C, Tolppanen H, Mebazaa A. Physiological changes in pregnancy. Cardiovasc J Afr. 2016;2:89–94.

Suvakov S, Kattah AG, Gojkovic T, Enninga EA, Pruett J, Jayachandran M, et al. Impact of aging and cellular senescence in the pathophysiology of preeclampsia. Compr Physiol. 2023;4:5077–114.

Wild R, Feingold KR. Effect of pregnancy on lipid metabolism and lipoprotein levels. Endotext [Internet]. 2023 [cited 2024 Dec 15]. Available from: https://www.ncbi.nlm.nih.gov/

books/NBK498654/

Herrera E, Ortega-Senovilla H. Maternal lipid metabolism during normal pregnancy and its implications to fetal development. Clin Lipidol. 2010;6:899–911.

Grantz KL, Elmi A, Pugh SJ, Catov JM, Sjaarda L, Albert PS. Maternal serum lipid trajectories and association with pregnancy loss and length of gestation. Am J Perinatol. 2020;9:914–23.

Woollett LA, Catov JM, Jones HN. Roles of maternal HDL during pregnancy. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;3:159–66.

Banait T, Wanjari A, Danade V, Banait S, Jain J. Role of high-sensitivity C-reactive protein (Hs-CRP) in non-communicable diseases: a review. Cureus. 2022;10:e29680.

Sack Jr GH. Serum amyloid A – a review. Mol Med. 2018;1:46.

Webb NR. High-density lipoproteins and serum amyloid A (SAA). Curr Atheroscler Rep. 2021;23:1–8.

Schuchardt M, Prüfer N, Tu Y, Herrmann J, Hu XP, Chebli S, et al. Dysfunctional high-density lipoprotein activates toll-like receptors via serum amyloid A in vascular smooth muscle cells. Sci Rep. 2019;9(1):3421.

Bardou M, Hadi T, Mace G, Pesant M, Debermont J, Barrichon M, et al. Systemic increase in human maternal circulating CD14+ CD16− MCP-1+ monocytes as a marker of labor. Am J Obstet Gynecol. 2014;1:70.e1.

Floeck A, Ferrari N, Joisten C, Puth MT, Strizek B, Dolscheid-Pommerich R, et al. Resistin in pregnancy: analysis of determinants in pairs of umbilical cord blood and maternal serum. Cytokine X. 2021;2:100052.

National Institute for Health and Clinical Excellence. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. NICE; 2010.

The American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2019;133:e1-25.

Sharma D, Shastri S, Sharma P. Intrauterine growth restriction: antenatal and postnatal aspects. Clin Med Insights Pediatr. 2016;10:67–83.

Katz ED, Ruoff BE. Commonly Used Formulas and Calculations. In: Roberts J, Hedges J, editors. Clinical Procedures in Emergency Medicine, 4th ed. Elsevier Mosby Publishing: Philadelphia, PA, USA, 2004; p. 1434.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.

Virani SS. Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges. Tex Heart Inst J. 2011;38(2):160.

English FA, Kenny LC, McCarthy FP. Risk factors and effective management of preeclampsia. Integr Blood Press Control. 2015;3:7–12.

De Kat AC, Hirst J, Woodward M, Kennedy S, Peters SA. Prediction models for preeclampsia: A systematic review. Pregnancy Hypertens. 2019;16:48–66.

Mayrink J, Souza RT, Feitosa FE, Rocha Filho EA, Leite DF, Vettorazzi J, et al. Mean arterial blood pressure: potential predictive tool for preeclampsia in a cohort of healthy nulliparous pregnant women. BMC Pregnancy Childbirth. 2019;19:1–8.

Mankuta D, Elami-Suzin M, Elhayani A, Vinker S. Lipid profile in consecutive pregnancies. Lipids Health Dis. 2010;9:1–4.

Bao W, Dar S, Zhu Y, Wu J, Rawal S, Li S, et al. Plasma concentrations of lipids during pregnancy and the risk of gestational diabetes mellitus: A longitudinal study. J Diabetes. 2018;6:487–95.

Sharami SH, Tangestani A, Faraji R, Zahiri Z, Amiri A. Role of dyslipidemia in preeclamptic overweight pregnant women. Iran J Reprod Med. 2012;2:105.

Melhem H, Kallol S, Huang X, Lüthi M, Ontsouka CE, Keogh A, et al. Placental secretion of apolipoprotein A1 and E: the anti-atherogenic impact of the placenta. Sci Rep. 2019;1:6225.

Gil-Acevedo L, Ceballos G, Torres-Ramos Y. Foetal lipoprotein oxidation and preeclampsia. Lipids Health Dis. 2022;21:51.

Diareme M, Karkalousos P, Theodoropoulos G, Strouzas S, Lazanas N. Lipid profile of healthy women during normal pregnancy. J Med Biochem. 2009;3:152–63.

Gugliucci A. Biomarkers of dysfunctional visceral fat. Adv Clin Chem. 2022;109:1–30.

Nien JK, Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Gotsch F, et al. Resistin: a hormone which induces insulin resistance is increased in normal pregnancy. J Perinat Med. 2007;6:513–21.

Siddiqui K, George TP. Resistin role in development of gestational diabetes mellitus. Biomarkers Med. 2017;7:579–86.

Parisi F, Milazzo R, Savasi VM, Cetin I. Maternal low-grade chronic inflammation and intrauterine programming of health and disease. Int J Mol Sci. 2021;4:1732.

Bogavac MA, Ćelić DD, Perić TM. A prospective study of mid-trimester MCP-1 levels as a predictor of preterm delivery. Medicines. 2022;1:7.

Garcia MS, Mobley Y, Henson J, Davies M, Skariah A, Dambaeva S, et al. Early pregnancy immune biomarkers in peripheral blood may predict preeclampsia. J Reprod Immunol. 2018;125:25–31.

Joshi K, Acharya N, Acharya S, Joshi S. Maternal serum high-sensitivity C-reactive protein (hsCRP) as a prognostic marker of fetomaternal outcome in hypertensive disorders of pregnancy: a novel study. Cureus. 2022;4:1–9.

Dhok AJ, Daf S, Mohod K, Kumar S. Role of early second trimester high sensitivity C-reactive protein for prediction of adverse pregnancy outcome. JK Sci. 2011;3:141–4.

Ebert R, Benisch P, Krug M, Zeck S, Meißner-Weigl J, Steinert A, et al. Acute phase serum amyloid A induces proinflammatory cytokines and mineralization via toll-like receptor 4 in mesenchymal stem cells. Stem Cell Res. 2015;1:231–9.

Lin YK, Zhu P, Wang WS, Sun K. Serum amyloid A, a host-derived DAMP in pregnancy? Front Immunol. 2022;13:978929.